Email: cspc@cspc.cn
News
April 25, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS
Next: VOLUNTARY ANNOUNCEMENT - JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us